Artal Group’s Neurocrine Biosciences NBIX Stock Holding History

Artal Group’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-200,000	Closed	-$16.9M	–	113
2019 Q2	$16.9M	Hold	200,000	–	–	0.68%	32
2019 Q1	$17.6M	Buy	+200,000	New	+$16.7M	0.72%	31
2018 Q2	–	Sell	-100,000	Closed	-$8.29M	–	113
2018 Q1	$8.29M	Buy	+100,000	New	+$8.44M	0.1%	55
2017 Q1	–	Sell	-100,000	Closed	-$3.87M	–	108
2016 Q4	$3.87M	Buy	+100,000	New	+$4.53M	0.09%	59

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's NBIX Position: Q1 2018 in Review

Artal Group sold out of Neurocrine Biosciences (NBIX) in Q1 2018, closing a stake of 250,000 shares — an estimated $21.1M sold.

Artal Group first reported a position in NBIX in Q2 2016 and held it in 7 quarters. The position peaked at $25.3M in Q2 2017. 267 funds tracked by Wall St. Rank hold NBIX as of Q1 2018.

Artal Group reported no remaining Neurocrine Biosciences position as of Q1 2018 after selling out during the quarter.
Artal Group sold 250,000 Neurocrine Biosciences shares in Q1 2018, an estimated $21.1M.
Artal Group first reported a position in Neurocrine Biosciences in Q2 2016 and held it in 7 quarters.
Artal Group's Neurocrine Biosciences position peaked at $25.3M in Q2 2017.
267 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2018.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.